Developer docs
API playgroundTry for free, no card

Search company profiles

Ractigen Therapeutics

Full company profile

uuid000298o

Namestring
Ractigen Therapeutics
Legal namestring
Ractigen Therapeutics
Websiteurl
ractigen.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Ractigen Therapeutics is a clinical-stage biopharmaceutical company headquartered in Nantong, China, founded in 2017 to commercialize RNA activation (RNAa) technology discovered by CEO Dr. Long-Cheng Li in 2006. The company develops small activating RNAs (saRNAs) and small interfering RNAs (siRNAs) that selectively turn genes on or off, addressing indications caused by insufficient protein expression or toxic gain-of-function mutations that are undruggable by conventional small molecules and biologics. Its core pipeline comprises RAG-01 (saRNA targeting p21 for non-muscle invasive bladder cancer, Phase II in China), RAG-17 (siRNA targeting SOD1 for ALS, Phase II dosed January 2026), RAG-18 (saRNA activating utrophin for Duchenne Muscular Dystrophy, IIT dosed December 2025), RAG-21 (siRNA targeting FUS for ALS, preclinical with FDA Orphan Drug Designation), and LiCO-saUcp1 (preclinical saRNA for obesity).

The company's competitive position rests on three proprietary delivery platforms: SCAD (Smart Chemistry-Aided Delivery) for CNS-administered duplex RNA, LiCO (Lipid-Conjugated Oligonucleotide) for extra-hepatic tissues via multiple administration routes, and GLORY. Ractigen has secured the first-ever FDA Fast Track Designation for an saRNA drug (RAG-01) along with three FDA Orphan Drug Designations and one Rare Pediatric Disease Designation, and operates clinical trial sites across China, Australia, and the United States with academic partners including Beijing Tiantan Hospital, Peking Union Medical College Hospital, GenesisCare Australia, and University Medical Center Utrecht. The company has not yet reached commercial stage; its revenue model contemplates future drug development and commercialization supplemented by potential licensing and royalty arrangements, supported by approximately $50 million in cumulative Series A and Series A+ venture financing led by Hillhouse Venture Capital and SDIC Venture Capital with strategic participation from Eisai Co., Ltd.

Short descriptiontext

Ractigen Therapeutics is a clinical-stage Chinese biopharmaceutical company pioneering RNA activation (saRNA) and siRNA therapeutics, with a five-asset pipeline spanning non-muscle invasive bladder cancer, ALS, Duchenne Muscular Dystrophy, and obesity, supported by proprietary CNS and extra-hepatic delivery platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA therapeutics, saRNA drug development, oligonucleotide delivery, gene activation therapy, clinical-stage biopharmaceutical
Industry4 codes
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
RNA Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeOne Time License
Description

Ractigen is a clinical-stage biopharmaceutical company developing RNA-based therapeutics. The company generates revenue through development and potential commercialization of its drug pipeline including RAG-01 (bladder cancer), RAG-17 (SOD1-ALS), RAG-18 (DMD), and other pipeline candidates. The company has not yet reached commercial stage.

ractigen.com
2Licensing and Partnerships
TypeLicensing Royalties
Description

The company may pursue licensing agreements and strategic partnerships for its technology platforms and drug candidates. Strategic partnerships with pharmaceutical companies and academic institutions may provide development funding and commercialization support.

ractigen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ractigen Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics using its proprietary RNA activation (RNAa) technology platform and small activating RNA (saRNA) compounds. The company builds and licenses proprietary delivery platforms—SCAD for CNS delivery, LiCO for extra-hepatic delivery, and GLORY—to advance first-in-class drug candidates targeting oncology, neurological, neuromuscular, and metabolic diseases. Its clinical pipeline includes RAG-01 (bladder cancer), RAG-17 (SOD1-ALS), RAG-18 (DMD/BMD), RAG-21 (FUS-ALS), and LiCO-saUcp1 (obesity).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • RAG-17 achieved 81.2% reduction in plasma neurofilament light chain (NfL) in 180mg cohort at Day 150
+4 more records
Product overview1 text field

Ractigen Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics primarily through its RNA activation (RNAa) technology platform. The company offers a portfolio of proprietary delivery platforms including SCAD™ for CNS delivery, LiCO™ for extra-hepatic delivery, and GLORY™. The core product pipeline includes: RAG-01 (saRNA for bladder cancer targeting p21), RAG-17 (siRNA for SOD1-ALS using SCAD™), RAG-18 (saRNA for DMD/BMD targeting UTRN using LiCO™), RAG-21 (siRNA for FUS-ALS using SCAD™), and LiCO-saUcp1 (saRNA for obesity). The company also licenses its RNAa technology and delivery platforms for therapeutic development across oncology, neurological diseases, and genetic disorders.

Product and service7 records
1RAG-01
CategoryRNA Therapeutics - Oncology
Description

RAG-01 is a pioneering saRNA therapeutic designed to upregulate the p21 tumor suppressor gene via RNA activation (RNAa) for treatment of non-muscle invasive bladder cancer (NMIBC). It is delivered through intravesical instillation using Ractigen's proprietary LiCO delivery technology. RAG-01 received FDA Fast Track Designation in May 2024 and FDA IND approval in April 2024.

2RAG-17
CategoryRNA Therapeutics - Neurology
Description

RAG-17 is an siRNA therapeutic designed to suppress SOD1 gene expression in ALS patients with pathogenic mutations. It utilizes Ractigen's proprietary SCAD delivery platform with accessory oligonucleotide (ACO) conjugation for enhanced CNS delivery. RAG-17 received FDA Orphan Drug Designation and China NMPA IND approval.

3RAG-18
CategoryRNA Therapeutics - Neuromuscular
Description

RAG-18 is a first-in-class saRNA candidate targeting UTRN gene activation in muscle cells via RNAa mechanism for treatment of Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Delivered using LiCO technology. RAG-18 received FDA Orphan Drug Designation and Rare Pediatric Disease Designation.

4RAG-21
CategoryRNA Therapeutics - Neurology
Description

RAG-21 is an siRNA therapy targeting FUS gene mutations for treatment of FUS-ALS, one of the most aggressive ALS subtypes. It is delivered via the SCAD platform for targeted, efficient, and durable gene knockdown in the CNS. RAG-21 received FDA Orphan Drug Designation.

5LiCO-saUcp1
CategoryRNA Therapeutics - Metabolic
Description

LiCO-saUcp1 is a first-in-class saRNA candidate for obesity that upregulates Ucp1 gene expression using the LiCO delivery platform, driving metabolic thermogenesis by converting white fat to calorie-burning brown fat. Demonstrated 45% fat mass reduction while preserving lean muscle mass in preclinical models.

6SCAD Delivery Platform
CategoryDrug Delivery Technology Platform
Description

SCAD (Smart Chemistry-Aided Delivery) is Ractigen's proprietary breakthrough platform technology for delivering duplex RNA therapeutics to the central nervous system by conjugating therapeutic duplex RNA to a non-targeting accessory oligonucleotide (ACO). Enables broad tissue distribution and cellular uptake without relying on complex lipids or antibodies.

7LiCO Delivery Platform
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Peking Union Medical College Hospital (PUMCH)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-12
Description

Lead site for investigator-initiated trial of RAG-18 for Duchenne Muscular Dystrophy. Trial led by Professor Dai Yi.

ractigen.com
2GenesisCare Australia
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-03
Description

Collaboration with GenesisCare, Australia's leading provider of cancer care services, for Phase I clinical trial of RAG-01 in non-muscle invasive bladder cancer patients.

ractigen.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-29
Description

Strategic collaboration to drive saRNA innovation in neurodevelopmental disorders. Partnership leverages Ractigen's saRNA discovery platform and Utrecht's research in genetic underpinnings of severe childhood epilepsies. Led by Professor Bobby Koeleman.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-10
Description

Lead site for investigator-initiated trial and Phase I clinical trial of RAG-17 for SOD1-ALS. Conducted under leadership of Dr. Yilong Wang.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

The global leader in RNAi therapeutics (siRNA), with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio). Directly comparable to Ractigen as the dominant RNA-based therapeutic company; Ractigen is differentiated by its saRNA (RNA activation) approach versus Alnylam's gene silencing modality.

TypeBroad incumbent
Description

Pioneer in antisense oligonucleotide (ASO) therapeutics with multiple approved products including Spinraza for SMA. Comparable to Ractigen as an established RNA-targeted therapeutic company working across neurological, neuromuscular, and rare disease indications — the same therapeutic areas Ractigen is pursuing with RAG-17 and RAG-18.

TypeDirect peer
Description

Clinical-stage siRNA company with proprietary extra-hepatic delivery platforms (TRiM platform) targeting the same tissues (lung, muscle, CNS, fat) as Ractigen's SCAD and LiCO platforms. Highly comparable as a delivery-platform-focused RNA therapeutics company with multiple clinical-stage assets.

TypeDirect peer
Description

Clinical-stage company developing antisense oligonucleotide-mediated exon inclusion to increase gene expression — the closest direct mechanistic analog to Ractigen's RNAa approach. Lead asset STK-001 targets Dravet syndrome, but the platform strategy of upregulating endogenous gene expression directly parallels Ractigen's RNAa mechanism for DMD and other indications.

TypeDirect peer
Description

Clinical-stage oligonucleotide therapeutics company with proprietary PRISM platform for siRNA, ASO, and AIMer-based gene upregulation approaches. Comparable to Ractigen in modality breadth, neurological focus (Huntington's, ALS, DMD), and stage of clinical development.

TypeDirect peer
Description

China-based clinical-stage RNAi therapeutics company developing siRNA therapies for oncology and fibrosis. Most directly comparable peer given shared China domicile, RNA therapeutic modality, clinical stage, and focus on oncology indications overlapping with Ractigen's RAG-01 program.

TypeDirect peer
Description

China-based clinical-stage siRNA company developing oligonucleotide therapeutics. Directly comparable to Ractigen as a Chinese clinical-stage RNA therapeutics peer pursuing similar therapeutic areas and with comparable funding stage and headcount.

TypeEmerging player
Description

Clinical-stage biotech using antisense oligonucleotides to upregulate gene expression via regulatory RNA (regRNA) — mechanistically the closest emerging competitor to Ractigen's RNAa approach. Targets rare neurological and metabolic diseases with similar therapeutic logic.

TypeBroad incumbent
Description

Major biopharmaceutical company with established ALS franchise including Qalsody (tofersen, approved for SOD1-ALS) — directly competitive with Ractigen's RAG-17 program in the same SOD1-ALS indication. Biogen also has broader oligonucleotide and antisense expertise through partnerships.

TypeBroad incumbent
Description

Approved DMD franchise (Exondys 51, Vyondys 53, Elevidys) competing with Ractigen's RAG-18 in the Duchenne Muscular Dystrophy indication. Comparable as an established neuromuscular disease oligonucleotide company with FDA-approved therapies in the same indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ractigen Therapeutics

RNA Therapeuticsractigen.com

Ractigen Therapeutics is a clinical-stage Chinese biopharmaceutical company pioneering RNA activation (saRNA) and siRNA therapeutics, with a five-asset pipeline spanning non-muscle invasive bladder cancer, ALS, Duchenne Muscular Dystrophy, and obesity, supported by proprietary CNS and extra-hepatic delivery platforms.

What Ractigen Therapeutics does

Ractigen Therapeutics is a clinical-stage biopharmaceutical company headquartered in Nantong, China, founded in 2017 to commercialize RNA activation (RNAa) technology discovered by CEO Dr. Long-Cheng Li in 2006. The company develops small activating RNAs (saRNAs) and small interfering RNAs (siRNAs) that selectively turn genes on or off, addressing indications caused by insufficient protein expression or toxic gain-of-function mutations that are undruggable by conventional small molecules and biologics. Its core pipeline comprises RAG-01 (saRNA targeting p21 for non-muscle invasive bladder cancer, Phase II in China), RAG-17 (siRNA targeting SOD1 for ALS, Phase II dosed January 2026), RAG-18 (saRNA activating utrophin for Duchenne Muscular Dystrophy, IIT dosed December 2025), RAG-21 (siRNA targeting FUS for ALS, preclinical with FDA Orphan Drug Designation), and LiCO-saUcp1 (preclinical saRNA for obesity).

The company's competitive position rests on three proprietary delivery platforms: SCAD (Smart Chemistry-Aided Delivery) for CNS-administered duplex RNA, LiCO (Lipid-Conjugated Oligonucleotide) for extra-hepatic tissues via multiple administration routes, and GLORY. Ractigen has secured the first-ever FDA Fast Track Designation for an saRNA drug (RAG-01) along with three FDA Orphan Drug Designations and one Rare Pediatric Disease Designation, and operates clinical trial sites across China, Australia, and the United States with academic partners including Beijing Tiantan Hospital, Peking Union Medical College Hospital, GenesisCare Australia, and University Medical Center Utrecht. The company has not yet reached commercial stage; its revenue model contemplates future drug development and commercialization supplemented by potential licensing and royalty arrangements, supported by approximately $50 million in cumulative Series A and Series A+ venture financing led by Hillhouse Venture Capital and SDIC Venture Capital with strategic participation from Eisai Co., Ltd.

Ractigen Therapeutics firmographics

Firmographics
Name
Ractigen Therapeutics
Legal name
Ractigen Therapeutics
Website
https://ractigen.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Ractigen Therapeutics is a clinical-stage Chinese biopharmaceutical company pioneering RNA activation (saRNA) and siRNA therapeutics, with a five-asset pipeline spanning non-muscle invasive bladder cancer, ALS, Duchenne Muscular Dystrophy, and obesity, supported by proprietary CNS and extra-hepatic delivery platforms.
Ownership category
akta.pro rank

Ractigen Therapeutics industry classification

Industry
Product category
RNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA therapeutics
  • SaRNA drug development
  • Oligonucleotide delivery
  • Gene activation therapy
  • Clinical-stage biopharmaceutical

Where Ractigen Therapeutics is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Ractigen Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Ractigen is a clinical-stage biopharmaceutical company developing RNA-based therapeutics. The company generates revenue through development and potential commercialization of its drug pipeline including RAG-01 (bladder cancer), RAG-17 (SOD1-ALS), RAG-18 (DMD), and other pipeline candidates. The company has not yet reached commercial stage.
  2. Licensing and Partnerships: The company may pursue licensing agreements and strategic partnerships for its technology platforms and drug candidates. Strategic partnerships with pharmaceutical companies and academic institutions may provide development funding and commercialization support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Ractigen Therapeutics product offering

Product offering

Core offering

Ractigen Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics using its proprietary RNA activation (RNAa) technology platform and small activating RNA (saRNA) compounds. The company builds and licenses proprietary delivery platforms—SCAD for CNS delivery, LiCO for extra-hepatic delivery, and GLORY—to advance first-in-class drug candidates targeting oncology, neurological, neuromuscular, and metabolic diseases. Its clinical pipeline includes RAG-01 (bladder cancer), RAG-17 (SOD1-ALS), RAG-18 (DMD/BMD), RAG-21 (FUS-ALS), and LiCO-saUcp1 (obesity).

Product overview

Ractigen Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics primarily through its RNA activation (RNAa) technology platform. The company offers a portfolio of proprietary delivery platforms including SCAD™ for CNS delivery, LiCO™ for extra-hepatic delivery, and GLORY™. The core product pipeline includes: RAG-01 (saRNA for bladder cancer targeting p21), RAG-17 (siRNA for SOD1-ALS using SCAD™), RAG-18 (saRNA for DMD/BMD targeting UTRN using LiCO™), RAG-21 (siRNA for FUS-ALS using SCAD™), and LiCO-saUcp1 (saRNA for obesity). The company also licenses its RNAa technology and delivery platforms for therapeutic development across oncology, neurological diseases, and genetic disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • RAG-01 RAG-01 is a pioneering saRNA therapeutic designed to upregulate the p21 tumor suppressor gene via RNA activation (RNAa) for treatment of non-muscle invasive bladder cancer (NMIBC). It is delivered through intravesical instillation using Ractigen's proprietary LiCO delivery technology. RAG-01 received FDA Fast Track Designation in May 2024 and FDA IND approval in April 2024.
  • RAG-17 RAG-17 is an siRNA therapeutic designed to suppress SOD1 gene expression in ALS patients with pathogenic mutations. It utilizes Ractigen's proprietary SCAD delivery platform with accessory oligonucleotide (ACO) conjugation for enhanced CNS delivery. RAG-17 received FDA Orphan Drug Designation and China NMPA IND approval.
  • RAG-18 RAG-18 is a first-in-class saRNA candidate targeting UTRN gene activation in muscle cells via RNAa mechanism for treatment of Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Delivered using LiCO technology. RAG-18 received FDA Orphan Drug Designation and Rare Pediatric Disease Designation.
  • RAG-21 RAG-21 is an siRNA therapy targeting FUS gene mutations for treatment of FUS-ALS, one of the most aggressive ALS subtypes. It is delivered via the SCAD platform for targeted, efficient, and durable gene knockdown in the CNS. RAG-21 received FDA Orphan Drug Designation.
  • LiCO-saUcp1 LiCO-saUcp1 is a first-in-class saRNA candidate for obesity that upregulates Ucp1 gene expression using the LiCO delivery platform, driving metabolic thermogenesis by converting white fat to calorie-burning brown fat. Demonstrated 45% fat mass reduction while preserving lean muscle mass in preclinical models.
  • SCAD Delivery Platform SCAD (Smart Chemistry-Aided Delivery) is Ractigen's proprietary breakthrough platform technology for delivering duplex RNA therapeutics to the central nervous system by conjugating therapeutic duplex RNA to a non-targeting accessory oligonucleotide (ACO). Enables broad tissue distribution and cellular uptake without relying on complex lipids or antibodies.
  • LiCO Delivery Platform

Quantifiable outcome

  • RAG-17 achieved 81.2% reduction in plasma neurofilament light chain (NfL) in 180mg cohort at Day 150
  • +4 more outcomes

Companies that use Ractigen Therapeutics

Customer profile

Segments4 records

Ideal customer profiles5 records

Ractigen Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ractigen Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Peking Union Medical College Hospital (PUMCH)coreStrategic or Co-development Partner · 12 December 2025Lead site for investigator-initiated trial of RAG-18 for Duchenne Muscular Dystrophy. Trial led by Professor Dai Yi.
  • GenesisCare AustraliacoreStrategic or Co-development Partner · 3 April 2024Collaboration with GenesisCare, Australia's leading provider of cancer care services, for Phase I clinical trial of RAG-01 in non-muscle invasive bladder cancer patients.
  • University Medical Center UtrechtcoreStrategic or Co-development Partner · 29 January 2024Strategic collaboration to drive saRNA innovation in neurodevelopmental disorders. Partnership leverages Ractigen's saRNA discovery platform and Utrecht's research in genetic underpinnings of severe childhood epilepsies. Led by Professor Bobby Koeleman.
  • Beijing Tiantan Hospital, Capital Medical UniversitycoreStrategic or Co-development Partner · 10 June 2023Lead site for investigator-initiated trial and Phase I clinical trial of RAG-17 for SOD1-ALS. Conducted under leadership of Dr. Yilong Wang.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Ractigen Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Alnylam Pharmaceuticals: The global leader in RNAi therapeutics (siRNA), with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio). Directly comparable to Ractigen as the dominant RNA-based therapeutic company; Ractigen is differentiated by its saRNA (RNA activation) approach versus Alnylam's gene silencing modality.
  • Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics with multiple approved products including Spinraza for SMA. Comparable to Ractigen as an established RNA-targeted therapeutic company working across neurological, neuromuscular, and rare disease indications — the same therapeutic areas Ractigen is pursuing with RAG-17 and RAG-18.
  • Biogen: Major biopharmaceutical company with established ALS franchise including Qalsody (tofersen, approved for SOD1-ALS) — directly competitive with Ractigen's RAG-17 program in the same SOD1-ALS indication. Biogen also has broader oligonucleotide and antisense expertise through partnerships.
  • Sarepta Therapeutics: Approved DMD franchise (Exondys 51, Vyondys 53, Elevidys) competing with Ractigen's RAG-18 in the Duchenne Muscular Dystrophy indication. Comparable as an established neuromuscular disease oligonucleotide company with FDA-approved therapies in the same indication.

Direct peers

  • Arrowhead Pharmaceuticals: Clinical-stage siRNA company with proprietary extra-hepatic delivery platforms (TRiM platform) targeting the same tissues (lung, muscle, CNS, fat) as Ractigen's SCAD and LiCO platforms. Highly comparable as a delivery-platform-focused RNA therapeutics company with multiple clinical-stage assets.
  • Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide-mediated exon inclusion to increase gene expression — the closest direct mechanistic analog to Ractigen's RNAa approach. Lead asset STK-001 targets Dravet syndrome, but the platform strategy of upregulating endogenous gene expression directly parallels Ractigen's RNAa mechanism for DMD and other indications.
  • Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company with proprietary PRISM platform for siRNA, ASO, and AIMer-based gene upregulation approaches. Comparable to Ractigen in modality breadth, neurological focus (Huntington's, ALS, DMD), and stage of clinical development.
  • Sirnaomics: China-based clinical-stage RNAi therapeutics company developing siRNA therapies for oncology and fibrosis. Most directly comparable peer given shared China domicile, RNA therapeutic modality, clinical stage, and focus on oncology indications overlapping with Ractigen's RAG-01 program.
  • Suzhou Ribo Life Science (Ribocure): China-based clinical-stage siRNA company developing oligonucleotide therapeutics. Directly comparable to Ractigen as a Chinese clinical-stage RNA therapeutics peer pursuing similar therapeutic areas and with comparable funding stage and headcount.

Emerging players

  • CAMP4 Therapeutics: Clinical-stage biotech using antisense oligonucleotides to upregulate gene expression via regulatory RNA (regRNA) — mechanistically the closest emerging competitor to Ractigen's RNAa approach. Targets rare neurological and metabolic diseases with similar therapeutic logic.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ractigen Therapeutics social profiles

Digital presence

Ractigen Therapeutics compliance and trust

Trust signal

Compliance8 records

Ractigen Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ractigen Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Ractigen Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ractigen Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ractigen Therapeutics

What does Ractigen Therapeutics do?

Ractigen Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics using its proprietary RNA activation (RNAa) technology platform and small activating RNA (saRNA) compounds. The company builds and licenses proprietary delivery platforms—SCAD for CNS delivery, LiCO for extra-hepatic delivery, and GLORY—to advance first-in-class drug candidates targeting oncology, neurological, neuromuscular, and metabolic diseases. Its clinical pipeline includes RAG-01 (bladder cancer), RAG-17 (SOD1-ALS), RAG-18 (DMD/BMD), RAG-21 (FUS-ALS), and LiCO-saUcp1 (obesity).

Is Ractigen Therapeutics a public or private company?

Ractigen Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ractigen Therapeutics founded?

Ractigen Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Ractigen Therapeutics based?

Ractigen Therapeutics is headquartered in Suzhou, China, in the Asia region.

How does Ractigen Therapeutics make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are licensing and Partnerships.

Who are Ractigen Therapeutics's main competitors?

Broad incumbents on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Biogen and Sarepta Therapeutics. Direct peers are Arrowhead Pharmaceuticals, Stoke Therapeutics, Wave Life Sciences, Sirnaomics and Suzhou Ribo Life Science (Ribocure). CAMP4 Therapeutics is listed as an emerging player.

Does Ractigen Therapeutics have an API?

No public API is recorded for Ractigen Therapeutics.

What industry is Ractigen Therapeutics in?

Ractigen Therapeutics's product category is RNA Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACRactigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder CancerRactigen Therapeutics initiated its multi-center Phase II trial of RAG-01 for non-muscle invasive bladder cancer in China, with a site initiation meeting at Fudan University Shanghai Cancer Center. The trial evaluates RAG-01 alone and with mitomycin C across 11 institutions. The company expects to assess efficacy, safety, and pharmacokinetics.PR NewswireRactigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder CancerRactigen Therapeutics initiated its multi-center Phase II trial of RAG-01 for non-muscle invasive bladder cancer at Fudan University Shanghai Cancer Center, with 11 Chinese centers participating. The study evaluates RAG-01 monotherapy and with mitomycin C, using 24-month event-free survival as the primary endpoint. The trial follows a safety run-in phase.PR Newswire APACRactigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy - Nucleic AcidsRactigen Therapeutics published a study in Molecular Therapy – Nucleic Acids on its LiCO platform for extrahepatic oligonucleotide delivery. The platform uses a benzimidazole-based linker and lipid conjugate to target skeletal muscle, heart, and adipose tissue. It is clinically validated in Phase I trials, including early complete responses in bladder cancer and positive proof-of-mechanism in Duchenne muscular dystrophy.PR NewswireRactigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy - Nucleic AcidsRactigen Therapeutics published a study in Molecular Therapy – Nucleic Acids detailing its LiCO platform for extrahepatic oligonucleotide delivery. The platform achieved ~90% target knockdown in non-human primates and is clinically validated in RAG-18 for Duchenne muscular dystrophy and RAG-01 for bladder cancer.PR Newswire APACRactigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular DystrophyRactigen Therapeutics presented positive first-in-human data for RAG-18 at WMS 2026, showing utrophin upregulation in three Duchenne muscular dystrophy patients. The saRNA safely entered skeletal muscle and improved muscle architecture, with Cohort 2 fully enrolled. The company aims to accelerate development for a disease-modifying therapy.Laotian TimesRactigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular DystrophyRactigen Therapeutics presented first-in-human data for RAG-18 at WMS 2026, showing safe upregulation of utrophin in Duchenne muscular dystrophy patients. Paired muscle biopsies revealed 3.5- to 5.3-fold increases in sarcolemmal utrophin, with zero dose-limiting toxicities and positive functional trajectories. Cohort 2 (30 mg) is fully enrolled, with safety follow-up ongoing.PR NewswireRactigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular DystrophyRactigen Therapeutics presented positive first-in-human data for RAG-18 at WMS 2026, showing that a systemically delivered saRNA safely upregulates utrophin in Duchenne muscular dystrophy. Paired muscle biopsies revealed 3.5- to 5.3-fold increases in sarcolemmal utrophin, with zero dose-limiting toxicities and zero serious adverse events. Cohort 2 (30 mg) is fully enrolled, and the company plans to accelerate clinical development.PR Newswire APACRactigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle SocietyRactigen Therapeutics announced that first-in-human data from its RAG-18 program in Duchenne muscular dystrophy will be presented as a late-breaking oral talk at the 31st World Muscle Society Congress in Hiroshima, Japan. The presentation will report Cohort 1 findings from the open-label dose-escalation trial, including safety, tolerability, and utrophin upregulation in muscle biopsies.PR NewswireRactigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle SocietyRactigen Therapeutics announced its first-in-human RNA activation data for Duchenne muscular dystrophy will be presented as a late-breaking oral session at the 31st World Muscle Society Congress in Hiroshima, Japan. The presentation will report Cohort 1 findings from the RAG-18 trial, including safety, tolerability, and utrophin upregulation in ambulatory boys.Neurology liveRactigen Completes Enrollment for RAG-17 in SOD1-ALS, Tanruprubart Shows Rapid Responses in GBS, Building a Multidisciplinary SMA ClinicRactigen Therapeutics announced the completion of patient enrollment and initial dosing for its phase 2 clinical trial of RAG-17, an siRNA therapy targeting SOD1 mutations in ALS. Concurrently, Annexon reported early results from its FORWARD study showing rapid clinical improvement in patients with Guillain-Barré syndrome treated with tanruprubart.